U.S. Markets open in 9 hrs 1 min
  • S&P Futures

    4,293.75
    -4.50 (-0.10%)
     
  • Dow Futures

    33,870.00
    -3.00 (-0.01%)
     
  • Nasdaq Futures

    13,667.25
    -14.00 (-0.10%)
     
  • Russell 2000 Futures

    2,022.90
    -0.90 (-0.04%)
     
  • Crude Oil

    88.86
    -0.55 (-0.62%)
     
  • Gold

    1,795.90
    -2.20 (-0.12%)
     
  • Silver

    20.20
    -0.07 (-0.36%)
     
  • EUR/USD

    1.0165
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    2.7910
    -2.8490 (-100.00%)
     
  • Vix

    19.95
    -19.53 (-100.00%)
     
  • GBP/USD

    1.2043
    -0.0015 (-0.1240%)
     
  • USD/JPY

    133.3820
    +0.1100 (+0.0825%)
     
  • BTC-USD

    24,053.17
    -744.27 (-3.00%)
     
  • CMC Crypto 200

    569.80
    -20.96 (-3.55%)
     
  • FTSE 100

    7,509.15
    +8.26 (+0.11%)
     
  • Nikkei 225

    28,841.69
    -30.09 (-0.10%)
     

Metadeq Announces Breakthrough Non-Invasive Blood Test that Solves NASH Diagnosis Problem

·4 min read

New test featured today in Gut, a leading international journal published by BMJ, uses A.I. to accurately predict the stages of the whole spectrum of liver diseases, from NAFLD to NASH and liver fibrosis

BOSTON, July 15, 2022 /PRNewswire/ -- Metadeq Inc., a global NASH and metabolic diseases diagnostics company, today announced a breakthrough non-invasive blood test that utilizes two novel circulating proteins to accurately diagnose Non-alcoholic steato-hepatitis (NASH) and liver fibrosis, and can score the stages of both diseases, without the need for invasive liver biopsy. The study which details the new blood test – just revealed in Gut, a leading hepatology and gastroenterology journal published by BMJ – was led by King's College London Professor Geltrude Mingrone, in collaboration with Metadeq.

Approximately one in four people worldwide, or approximately two billion people, have Non-alcoholic fatty liver disease (NAFLD) and therefore are at risk of developing NASH. NASH is the most severe form of NAFLD, a silent disease associated with fatty deposit build-up of the liver. NASH leads to advanced liver diseases such as liver fibrosis (scarring), cirrhosis, and liver cancer, and may ultimately result in death. The annual cost to the US healthcare system alone has been estimated to be over $100 billion per year.

Currently, the only way to diagnose NASH is through the standard of diagnosis, invasive liver biopsy, which is expensive and is associated with significant complications and discomfort. Until now, no reliable blood test has been developed for NASH, nor liver fibrosis. Most importantly, no available test can define the severity (stage), or monitor the progression, of either NASH or liver fibrosis.

Professor Geltrude Mingrone from the School of Cardiovascular and Metabolic Medicine & Sciences at King's College London, who is one of the most widely cited and influential researchers globally for metabolic diseases and disorders, set out to discover a more accurate liquid biopsy test in support of patient care and in collaboration with Metadeq. The resulting study was published today in leading journal, Gut.

This study identified two novel protein biomarkers, PLIN2 and RAB14, to assist in the diagnosis of patients with NASH and/or liver fibrosis. The ability of these proteins to detect both diseases was tested in cohorts with either NASH and/or liver fibrosis that were confirmed with liver biopsy, the current standard of diagnosis.

"This blood test will allow researchers and clinicians to define the prevalence of NASH across populations, including children and adolescents, avoiding the need for invasive liver biopsy," said Professor Mingrone. "Critically, it will allow care-givers to monitor the efficacy of NASH treatments over time, reducing screen failures and helping generate better drugs."

"Since HEPAR-QTM is the only diagnostic modality that can diagnose NASH and fibrosis staging we expect it to be instrumental in the development of new therapeutics for the management of patients," said Frank Jaksch, Chairman of Metadeq. "We believe that HEPAR-QTM will advance for the benefit of patients the problem of regular screening, that has resulted in late drug failures during clinical trials, since it is now possible to accurately measure the severity of disease in a non-invasive manner."

The Metadeq predictive algorithm, which uses A.I., provided unprecedented sensitivity (88-95%), specificity (90-100%), and overall accuracy (92-93%) for NASH, and also has near-perfect sensitivity (99%-100%), specificity (90%-96%), and accuracy (98%-99%) for liver fibrosis.

The test results show that the proteins can provide rapid and cost-effective testing to combat the growing epidemic of NASH and liver fibrosis. This could be an invaluable tool in diagnosing and monitoring cases of liver diseases, allowing people to receive earlier treatment, from lifestyle adjustments to surgical and pharmacological interventions.

Currently no NASH drug has been approved by either the FDA or EMA, which may be a direct result of the lack of an accurate, reliable, and non-invasive test. More than 65% of patients who enroll in clinical trials for NASH-related therapies are found to be ineligible for the trial due to screen failure, which causes major monetary losses to companies developing and testing NASH drugs. The improved accuracy and ability to detect NASH staging will help in identifying and enrolling the appropriate people in clinical trials, speeding up the development of NASH drugs.

About Metadeq

Metadeq Corp. is a diagnostics company that provides innovative liquid biopsy solutions for liver and metabolic diseases. For the first time, Metadeq allows people to measure the whole spectrum of liver diseases – from NAFLD, to NASH, and liver fibrosis – with a blood test. www.metadeq.com

For an interview with Metadeq and their academic partners, please contact:

Stacey Doss, APR
SDDPR
stacey@sddpr.com
949-285-2362

To view the Gut article, please visit: Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis.

To view the King's College London press release, please visit King's researchers create highly accurate non-invasive test for major liver diseases.

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/metadeq-announces-breakthrough-non-invasive-blood-test-that-solves-nash-diagnosis-problem-301587569.html

SOURCE Metadeq